Comparative efficacy and safety of second- and later-line BRAF-targeted regimens in BRAF V600E-mutant metastatic colorectal cancer: A systematic review and network meta-analysis.
A simpler two-drug combination treats BRAF-mutant colorectal cancer as effectively as a three-drug regimen while causing fewer side effects.
A network meta-analysis of 4 trials enrolling 922 patients with BRAF V600E-mutant metastatic colorectal cancer found all encorafenib-based regimens significantly improved progression-free survival over irinotecan+cetuximab, with encorafenib+cetuximab ranking best for tolerability (OR 0.67 for grade ≥3 AEs). No significant difference was detected between encorafenib+binimetinib+cetuximab and encorafenib+cetuximab on efficacy endpoints, positioning the doublet as the preferred reference standard for previously treated BRAF V600E-mutant mCRC.
What the study was
- Study design
- systematic_review_network_meta_analysis
- Category
- precision_oncology_genomic_medicine
- Maturity
- Potentially Practice-Changing
- Journal
- Medicine (Baltimore)
Why it surfaced
NMA consolidates evidence for BRAF V600E mCRC treatment ladder; positions encorafenib+cetuximab as reference standard with best tolerability profile; directly informs treatment selection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.